At 14.2% CAGR, the Middle East & Africa T Cell Therapy Market is Projected to be Worth US$ 211.46 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa T cell therapy market was valued at US$ 73.14 million in 2022 and is expected to reach US$ 211.46 million by 2030, registering a CAGR of 14.2% from 2022 to 2030. Growing burden of cancer worldwide and increasing number of approval of t-cell therapies are the critical factors attributed to the Middle East & Africa T cell therapy market expansion.             

According to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. According to the International Agency of Research on Cancer, in 2040, 30.2 million new cases will be added to the global cancer burden. Chimeric antigen receptor (CAR) T-cell therapies can potentially treat new type of cancer treatment that uses the immune system to fight cancer. CAR T involves genetically engineering T cells to express a chimeric antigen receptor targeting a specific tumor antigen. T-cell-based techniques are frequently used in cancer immunotherapy due to their higher success rate. In 2021, Labiotech.eu (a leading online media for the biotech industry in Europe) stated that more than 500 CAR T-cells clinical trials for cancer treatment are being carried out globally. Thus, the growing burden of cancer is driving the T-cell therapy market.

On the contrary, side-effects of CAR T-cell therapy hampers on the growth of Middle East & Africa T cell therapy market. 

Based on modality, the Middle East & Africa T cell therapy market is bifurcated into research and commercialized. The commercialized segment held 89.8% market share in 2022, amassing US$  65.67 million. It is projected to garner US$ 194.07 million by 2030 to expand at 14.5% CAGR during 2022–2030.

Based on therapy type, the Middle East & Africa T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held 100.0% share of Middle East & Africa T cell therapy market in 2022, amassing US$ 73.14 million. It is projected to garner US$ 211.46 million by 2030 to expand at 14.2% CAGR during 2022–2030.

Based on indication, the Middle East & Africa T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held 100.0% share of Middle East & Africa T cell therapy market in 2022, amassing US$ 73.14 million. It is projected to garner US$ 211.46 million by 2030 to expand at 14.2% CAGR during 2022–2030.

Based on country, the Middle East & Africa T cell therapy market has been categorized into Saudi Arabia, Israel, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 70.6% share of Middle East & Africa T cell therapy market in 2022. It was assessed at US$ 51.62 million in 2022 and is likely to hit US$ 151.97 million by 2030, exhibiting a CAGR of 14.5% during 2022–2030.            

Key players operating in the Middle East & Africa T cell therapy market are Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com